Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
Authors
Keywords
-
Journal
Advanced Healthcare Materials
Volume -, Issue -, Pages 1801509
Publisher
Wiley
Online
2019-02-14
DOI
10.1002/adhm.201801509
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
- (2018) Robert R. Henry et al. DIABETES CARE
- A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide
- (2018) Tine A. Bækdal et al. Expert Opinion on Drug Metabolism & Toxicology
- Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action
- (2018) Caslin A. Gilroy et al. JOURNAL OF CONTROLLED RELEASE
- Biomacromolecules as carriers in drug delivery and tissue engineering
- (2018) Yujie Zhang et al. Acta Pharmaceutica Sinica B
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current and Emerging Technology for Continuous Glucose Monitoring
- (2017) Cheng Chen et al. SENSORS
- Glucose Sensing for Diabetes Monitoring: Recent Developments
- (2017) Danielle Bruen et al. SENSORS
- Synthetic “smart gel” provides glucose-responsive insulin delivery in diabetic mice
- (2017) Akira Matsumoto et al. Science Advances
- One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
- (2017) Kelli M. Luginbuhl et al. Nature Biomedical Engineering
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability
- (2016) Matthew C. Riddle DIABETES CARE
- Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and
- (2016) M. A. Boustani et al. DIABETES OBESITY & METABOLISM
- Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action
- (2016) S. J. Jacober et al. DIABETES OBESITY & METABOLISM
- Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
- (2016) David Rodbard Diabetes Technology & Therapeutics
- Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
- (2016) Johan Jendle et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
- (2016) Peng Zhang et al. JOURNAL OF CONTROLLED RELEASE
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
- (2016) Peter L. Turecek et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
- (2016) Wing Yan So et al. MEDICINAL RESEARCH REVIEWS
- How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
- (2016) Araceli Muñoz-Garach et al. Diabetes Therapy
- How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
- (2016) Araceli Muñoz-Garach et al. Diabetes Therapy
- A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity
- (2016) Yizhi Qi et al. Nature Biomedical Engineering
- Factors affecting therapeutic compliance: A review from the patient’s perspective
- (2016) Shu-Chuen Li Therapeutics and Clinical Risk Management
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
- (2015) William R. Strohl BIODRUGS
- Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
- (2015) Lisbeth V. Jacobsen et al. CLINICAL PHARMACOKINETICS
- The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
- (2015) CJ Bailey CLINICAL PHARMACOLOGY & THERAPEUTICS
- Protein–polymer conjugation—moving beyond PEGylation
- (2015) Yizhi Qi et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Peptide therapeutics: current status and future directions
- (2015) Keld Fosgerau et al. DRUG DISCOVERY TODAY
- Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2015) Hannah A. Blair et al. DRUGS
- Smart approaches to glucose-responsive drug delivery
- (2015) Matthew J. Webber et al. JOURNAL OF DRUG TARGETING
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Five-Year Efficacy and Safety Data of Exenatide Once Weekly
- (2015) Carol H. Wysham et al. MAYO CLINIC PROCEEDINGS
- Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery
- (2015) Jicheng Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fc fusion as a platform technology: potential for modulating immunogenicity
- (2015) Ditza Levin et al. TRENDS IN BIOTECHNOLOGY
- Degludec: the new ultra-long insulin analogue
- (2015) Marcos Antonio Tambascia et al. Diabetology & Metabolic Syndrome
- Challenges Associated with Insulin Therapy in Type 2 Diabetes Mellitus
- (2014) Steven Edelman et al. AMERICAN JOURNAL OF MEDICINE
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
- (2014) Robert R. Henry et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
- (2014) Emma M. Pelegri-O’Day et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Inventing new medicines: The FGF21 story
- (2014) Alexei Kharitonenkov et al. Molecular Metabolism
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Predicting Transition Temperatures of Elastin-Like Polypeptide Fusion Proteins
- (2013) Trine Christensen et al. BIOMACROMOLECULES
- A Unified Model for De Novo Design of Elastin-like Polypeptides with Tunable Inverse Transition Temperatures
- (2013) Jonathan R. McDaniel et al. BIOMACROMOLECULES
- A New-Generation Continuous Glucose Monitoring System: Improved Accuracy and Reliability Compared with a Previous-Generation System
- (2013) Mark Christiansen et al. Diabetes Technology & Therapeutics
- Burden of treatment for chronic illness: a concept analysis and review of the literature
- (2013) Adem Sav et al. HEALTH EXPECTATIONS
- A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
- (2013) M. Amiram et al. JOURNAL OF CONTROLLED RELEASE
- Sortase-Catalyzed Initiator Attachment Enables High Yield Growth of a Stealth Polymer from the C Terminus of a Protein
- (2013) Yizhi Qi et al. MACROMOLECULAR RAPID COMMUNICATIONS
- Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control
- (2013) M. Amiram et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
- (2012) R. M. Bergenstal et al. DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence
- (2012) A. R. Meloni et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Fc-fusion proteins: new developments and future perspectives
- (2012) Daniel M. Czajkowsky et al. EMBO Molecular Medicine
- Oral delivery of therapeutic protein/peptide for diabetes – Future perspectives
- (2012) M.R. Rekha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Efficacy and safety of ultra-long-acting insulin degludec
- (2012) Ammar Wakil et al. Therapeutic Advances in Endocrinology and Metabolism
- FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
- (2011) J. Mu et al. DIABETES
- Glucose and pH dual-responsive concanavalin A based microhydrogels for insulin delivery
- (2011) Ruixue Yin et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
- (2010) Katrin Knop et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Elastin-like polypeptides: Biomedical applications of tunable biopolymers
- (2010) Sarah R. MacEwan et al. BIOPOLYMERS
- A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects
- (2010) A. Khedkar et al. DIABETES OBESITY & METABOLISM
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Liraglutide
- (2010) Daniel J. Drucker et al. NATURE REVIEWS DRUG DISCOVERY
- Chemical generation of bispecific antibodies
- (2010) V. R. Doppalapudi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
- (2009) Volker Schellenberger et al. NATURE BIOTECHNOLOGY
- In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics
- (2009) W. Gao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started